|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment显示文摘BACKGROUND:Hepatocellular carcinoma(HCC) is a complex and heterogeneous malignancy,frequently occurs in the setting of a chronically diseased organ,with multiple confounding factors making its management challenging.HCC represents one of the leading causes of cancer-related mortality globally with a rising trend of incidence in some of the developed countries,which indicates the need for better surgical and nonsurgical management strategies.DATA SOURCES:Pub Med database was searched for relevant articles in English on the issue of HCC management.RESULTS:Surgical resection represents a potentially curative option for appropriate candidates with tumors detected at earlier stages and with well-preserved liver function.The long-term outcome of surgery is impaired by a high rate of recurrence.Surgical approaches are being challenged by local ablative therapies such as radiofrequency ablation and microwave ablation in selected patients.Liver transplantation offers potential cure for HCC and also correction of underlying liver disease,and minimizes the risk of recurrence,but is reserved for patients within a set of criteria proposed for a prudent allocation in the shortage of donor organs.Transcatheter locoregional therapies have become the palliative standard allowing local control for intermediate stage patients with noninvasive multinodular or large HCC who are beyond the potentially curative options.The significant survival benefit with the multikinase inhibitor sorafenib for advanced HCC has shifted the direction of research regarding systemic treatment toward molecular therapies targeting the disregulated pathways of hepatocarcinogenesis.Potential benefit is suggested from simultaneous or sequential multimodal therapies,and optimal combinations are being investigated.Despite the striking progress in preclinical studies of HCC immunotherapy and gene therapy,extensive clinical trials are required to achieve successful clinical applications of these innovative approaches.CONCLUSION:Treatment decisions have become increasingly complex for HCC with the availability of multiple surgical and nonsurgical therapeutic options and require a comprehensive,multidisciplinary approach. | Ender Gunes Yegin Erkan Oymac1 Emrah Karatay Ahmet Coker | 2016 | Hepatobiliary & Pancreatic Diseases International2016，15，3： | 14 |
| 2 | Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B显示文摘BACKGROUND: The definition of partial virological response(PVR) was proposed because of its clinical relevance. PVR relates to subsequent therapeutic failure which results in the modification of the regimen. Whether this rationale can be applied to all nucleotide analogues (NA) is not clear. This study was undertaken to analyze PVR influence on therapeutic outcomes during lamivudine, entecavir or tenofovir mono therapy in NA-naive patients with chronic hepatitis B in routine clinical practice.METHODS: We retrospectively analyzed 150 NA-naive patients with chronic hepatitis B. These subjects received lamivudine entecavir or tenofovir monotherapy between February 2001 and July 2013.RESULTS: Sixty-nine patients were treated with lamivudine, 35with entecavir, and 46 with tenofovir. The median therapeutic duration was 19.5 (6-147) months. PVR rates at 24 weeks were similar among three NAs (lamivudine 33.3%, entecavir 35.0%tenofovir 32.4%, P=0.981). For all three NAs, patients with a higher baseline viral load or HBeA g-positive status had a higher serum viral positive rate tested by polymerase chain reaction at week 24 and 48. Cumulative probability of virological breakthrough (VBR) for patients treated with lamivudine was67% at 5 years, and PVR at 24 weeks was the independent risk factor for VBR (HR: 3.09; 95% CI: 1.09-8.74; P=0.034); also lamivudine treated patients older than 50 years seemed to have a tendency for VBR (HR: 2.80; 95% CI: 0.99-8.18; P=0.052)A majority of entecavir and tenofovir partial responders achieved and maintained virological response with prolonged monotherapy, except one entecavir treated patient who experienced VBR due to resistance mutations.CONCLUSIONS: Management strategy for lamivudine treatment should include adaptation of regimen according to PVR as an on-treatment response parameter due to its relation with unacceptably high VBR probability. Similar conclusion should not be directly related to entecavir or tenofovir treatment. | Ender G Yegin Osman Cavit Ozdogan | 2014 | Hepatobiliary & Pancreatic Diseases International2014，13，6： | 5 |
| 3 | Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients显示文摘AIM: To investigate the frequency of occult hepatitis B, the clinical course of hepatitis B virus (HBV) reactivation and reverse seroconversion and associated risk factors in autologous hematopoietic stem cell transplantation (HSCT) recipients. METHODS: This study was conducted in 90 patients undergoing autologous HSCT. Occult HBV infection was investigated by HBV-DNA analysis prior to transplantation, while HBV serology and liver function tests were screened prior to and serially after transplantation. HBV-related events including reverse seroconversion and reactivation were recorded in all patients. RESULTS: None of the patients had occult HBV prior to transplantation. Six (6.7%) patients were positivefor HBV surface antigen (HBsAg) prior to transplantation and received lamivudine prophylaxis; they did not develop HBV reactivation after transplantation. Clinical HBV infection emerged in three patients after transplantation who had negative HBV-DNA prior to HSCT. Two of these three patients had HBV reactivation while one patient developed acute hepatitis B. Three patients had anti-HBc as the sole hepatitis B-related antibody prior to transplantation, two of whom developed hepatitis B reactivation while none of the patients with antibody to HBV surface antigen (anti-HBs) did so. The 14 anti-HBs-and/or anti-HBc-positive patients among the 90 HSCT recipients experienced either persistent (8 patients) or transient (6 patients) disappearance of anti-HBs and/or anti-HBc. HBsAg seroconversion and clinical hepatitis did not develop in these patients. Female gender and multiple myeloma emerged as risk factors for loss of antibody in regression analysis (P < 0.05). CONCLUSION: Anti-HBc as the sole HBV marker seems to be a risk factor for reactivation after autologous HSCT. Lamivudine prophylaxis in HbsAg-positive patients continues to be effective. | zcan eneli Zübeyde Nur zkurt Kadir Acar Seyyal Rota Sahika Zeynep Aki Zeynep Arzu Yegin Münci Yagci Seren zenirler Gülsan Türkz Sucak | 2010 | World Journal of Gastroenterology2010，16，14： | 3 |
| 4 | SOX4 expression levels in urothelial bladder carcinoma 显示文摘 | Gunes S Yegin Z Sullu Y Buyukalpelli R Bagci H | 2011 | Pathol Res Pract2011，207，7： | 1 |
| 5 | Biogenic amine content of boza: A traditional cereal-based, fermented Turkish beverage显示文摘 | Yegin S Uren A | 2008 | Food Chemistry2008，111，4： | 1 |
| 6 | Benchmark- ing brachydose voxel based EGSnrc Monte Carlo calculations of TG-43 dosimetry parameters 显示文摘 | Taylor REP Yegin G Rogers DwO | 2007 | Med Phys2007，34，2： | 1 |
| 7 | Early postoperative pain man- agement after thoracic surgery; pre-and postoperative versus postop- erative epidural analgesia: a randomised study显示文摘 | Yegin A Erdogan A Kayaean N | 2003 | Eur J Cardiotho- rac Surg2003，24，3： | 1 |
| 8 | Lipid nanocapsule size analysis by hydrody-namic chromatography and photon correlation spectroscopy 显示文摘 | Yegin BA Lamprecht A | 2006 | Int JPharm2006，320，12： | 1 |
| 9 | High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates显示文摘 | Tun?can OG Yegin ZA Ozkurt ZN | 2010 | Int J Infect Dis2010，14，3： | 1 |
| 10 | Lipid nanocapsule size analysis by hydrodynamic chromatography and photon correlation spectroscopy 显示文摘 | Yegin B A Lamprecht A | 2006 | International Journal of Pharmaeeutics2006，320，12： | 1 |
| 11 | Subintimal angioplasty of long superficial femoral artery occlusions显示文摘 | Yilmaz S Sindel T Yegin A | | 0，，08： | 1 |
| 12 | Surgical management of tuberculosisrelatedhemoptysis显示文摘 | Erdogan A Yegin A Gurses G | 2005 | Ann Thorac Surg2005，79，： | 1 |
| 13 | Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model 显示文摘 | Yegin A Akbas S H Ozben T | 2002 | Acta Neurol Scand2002，106，5： | 1 |
| 14 | Impact of ABO-in- compatible donor on early and late outcome of hematopoietic stem cell transplantation显示文摘 | Ozkurt ZN Yegin ZA Yenicesu I | 2009 | Transplant Proc2009，41，9： | 1 |
| 15 | The routine use of pediat- ric airway exchange catheter after extubation of adult patients who have undergone maxillofacial or major neck surgery: a clinical ob- servational study显示文摘 | Dosemeci L Yilmaz M Yegin A | 2004 | Crit Care2004，8，11： | 1 |
| 16 | Subintimal angioplasty of long superficial femoral artery occlusions显示文摘 | Yilmaz S Sindel T Yegin A | 2003 | J Vasc Interv Radiol2003，14，8： | 1 |
| 17 | Impact of ABO - incom- patible donor on early and late outcome of hematopoietic stem cell transplantation显示文摘 | Ozkurt ZN Yegin ZA Yenicesu I | 2009 | Transplant Proc2009，41，9： | 1 |
| 18 | Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging显示文摘 | Yegin E G Siykhymbayev A Eren F | | 0，，06： | 1 |
| 19 | Early postoperative pain management after thoracic surgery;pre-and postoperative versus postoperative epidural analgesia:a randomized study显示文摘 | Yegin A Erdogan A Kayacan N | 2003 | Eur J Cardiothorac Surg2003，24，： | 1 |
| 20 | Biogeuic amine content of boza: a traditional cereal-based, fermented Turkish beverage 显示文摘 | YEGIN S UREN A | 2008 | Food Chem2008，111，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员